<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05061875</url>
  </required_header>
  <id_info>
    <org_study_id>FIS-CEF-2021-01</org_study_id>
    <nct_id>NCT05061875</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Ceftriaxone Free Fraction</brief_title>
  <acronym>Infections</acronym>
  <official_title>Pharmacokinetics of Ceftriaxone Free Fraction Administered at High for the Treatment of Serious Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective observational follow-up study for the study and modeling of the pharmacokinetics&#xD;
      of the free fraction of ceftriaxone in patients treated with high doses of ceftriaxone&#xD;
      (greater than or equal to 4 grams per day).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective follow-up observational study to study and model the pharmacokinetics of the&#xD;
      ceftriaxone free fraction in patients treated with high doses of ceftriaxone (greater than or&#xD;
      equal to 4 grams per day). it is a pilot study that has between 10 and 20 patients. This&#xD;
      study will not condition the treatment of patients at any time.&#xD;
&#xD;
      The samples will be processed after their extraction. The concentration of the samples will&#xD;
      be analyzed using a high-performance gilent infinity liquid chromatograph coupled to a mass&#xD;
      spectrometer using positive or negative ionization using electrospray.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration [Cmax]</measure>
    <time_frame>Up to 24 weeks.</time_frame>
    <description>Determine the maximum plasma concentration of ceftriaxone after the administration of high doses (equal to or greater than 4 grams / day).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the plasma concentration of the free fraction of ceftriaxone 24 hours after the administration of the daily dose (trough level) in patients receiving doses equal to or greater than 4 grams / day.</measure>
    <time_frame>Up to 24 weeks.</time_frame>
    <description>Plasma concentration of the free fraction of ceftriaxone after 24 hours of the start of the daily dose (trough level) in patients treated with doses at or above 4 grams / day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the plasma concentration of the free fraction of ceftriaxone during 24 hours in patients receiving doses equal to or greater than 4 grams / day.</measure>
    <time_frame>Up to 24 weeks.</time_frame>
    <description>Plasma concentration of the free fraction of ceftriaxone for 24 hours in patients receiving doses equal to or greater than 4 grams / day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ceftriaxone plasma clearance.</measure>
    <time_frame>Up to 24 weeks.</time_frame>
    <description>determine the plasma clearance of ceftriaxone in patients receiving doses equal to or greater than 4 grams / day.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ceftriaxone Poisoning</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Patients treated with ceftriaxone doses equal to or higher 4 grams / day.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with ceftriaxone doses equal to or higher 4 grams / day. This study will&#xD;
        in no case condition the treatment of patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women over 55 years of age receiving treatment with high-dose ceftriaxone&#xD;
             (minimum 4 grams / day) for any clinical indication in the study period.&#xD;
&#xD;
          -  Creatinine &lt;1.5 mg / dL&#xD;
&#xD;
          -  The patient must have received at least 48 hours of treatment with the same previous&#xD;
             therapeutic regimen to extraction.&#xD;
&#xD;
          -  The subject or her representative must give their verbal or written consent to&#xD;
             participate in the study. East Consent can be revoked at any time without prejudice to&#xD;
             the patient.&#xD;
&#xD;
        The consent it will be recorded in your medical record.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under 55 years of age.&#xD;
&#xD;
          -  Creatinine&gt; 1.5 mg / dL&#xD;
&#xD;
          -  Patient with less than 48 hours of treatment with high-dose ceftriaxone.&#xD;
&#xD;
          -  Subjects with allergy or hypersensitivity to cephalosporins and penicillins.&#xD;
&#xD;
          -  Subjects who do not grant or withdraw their consent.&#xD;
&#xD;
          -  Patients whose concomitant treatment presents possible interactions with the study&#xD;
             medication. The possible interactions will be evaluated by staff of the Pharmacy&#xD;
             Service.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Maria Victoria Gil Navarro</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospitales Universitarios Virgen del Rocío</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Victoria Gil Navarro</last_name>
    <phone>955012300</phone>
    <email>mariav.gil.sspa@juntadeandalucia.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlos García Pérez</last_name>
    <phone>955 04 31 27</phone>
    <email>administracion.eecc.hvm.sspa@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Victoria Gil Navarro</last_name>
      <phone>955012300</phone>
      <email>mariav.gil.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poisoning</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

